Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data
Executive Summary
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.
You may also be interested in...
Alnylam’s Amvuttra To Take Off From Onpattro’s Runway
The company won approval in hATTR amyloidosis polyneuropathy for the RNAi drug, which offers quarterly subcutaneous dosing versus Onpattro’s I.V. administration every three weeks.
April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs
Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.
Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.